98%
921
2 minutes
20
Objective: This survey was performed to assess the level of influenza vaccine coverage, to understand the driving forces and barriers to vaccination and determine vaccination interventions for the following year in Korean population.
Methods: A national sample of 1720 community dwelling adults of age 18 and older were surveyed by individual visits during April 2005. Demographics, state of influenza vaccination, reasons for vaccination or non-vaccination and perceptions on vaccinations were asked by questionnaire.
Results: Influenza vaccination coverage in general population and high risk group was 34.3% and 61.3%, respectively. Predictors for vaccination were > or =65 of age, performance of regular exercise, vaccination in the previous season, experience of influenza-like illness, belief that vaccine can prevent common cold and opinion that vaccine must be taken annually. The most common reason for vaccination for both whole population and high risk groups was to prevent both influenza and common cold, while the most common reason for non-vaccination was the thought that he/she was healthy enough not to be in need for vaccination. Having more information on influenza and vaccination as well as doctor's recommendation for vaccination appeared to be the most important modus operandi to encourage influenza vaccination among non-vaccinees.
Conclusions: Doctor's recommendation was the most important factor in encouraging people to be vaccinated against influenza. Doctors should be geared up with precise information and actively encourage high risk population in order to increase vaccination coverage.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132372 | PMC |
http://dx.doi.org/10.1016/j.jinf.2007.04.354 | DOI Listing |
Influenza Other Respir Viruses
September 2025
Public Health Agency, Belfast, UK.
Background: We evaluated the effectiveness of the influenza vaccine programme against infection among emergency hospital admissions with respiratory conditions in Northern Ireland during the 2023/2024 influenza season.
Methods: Using a test-negative design, we compared the odds of vaccination between patients who tested positive (cases) and negative (controls) for laboratory-confirmed influenza, adjusting for confounders. VE was stratified by age group, sex and time since vaccination.
J Infect Chemother
September 2025
Department of Pediatrics, Saku Central Hospital Advanced Care Center, Nagano, Japan.
Background: Influenza remains a major public health issue, leading to millions of severe cases and many deaths annually. Although educational and childcare institutions are key transmission points for the spread of the virus in communities, few studies have comprehensively examined the vaccination rates and their determinants in these settings.
Methods: We conducted a nationwide web-based survey to assess influenza knowledge, perceptions, and determinants of vaccine hesitancy based on the 5C model among childcare and educational professionals in Japan.
Chest
September 2025
Child and Maternal Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Northern Territory, Australia; School of Nursing and Midwifery, Charles Darwin University, Darwin, Northern Territory, Australia.
Background: Managing bronchiectasis exacerbations is a priority for patients/parents/caregivers of children with bronchiectasis, yet evidence-based strategies among the pediatric population remain limited.
Research Question: Does the use of a personalized, written bronchiectasis action management plan (BAMP), compared to standard care, reduce non-scheduled doctor visits among children/adolescents with chronic suppurative lung disease (CSLD)/bronchiectasis?
Study Design And Methods: Our multicenter, double-blind, superiority, randomized controlled trial enrolled children from three Australian respiratory departments between June 2018 and December 2020. Children/adolescents aged <19 years with CSLD/bronchiectasis were randomized to receive a personalized BAMP (intervention) or standard care (controls).
J Control Release
September 2025
Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA; Bioinnovations in Brain Cancer, Biointerfaces Institute; The Developmental Therapeutics Program, Rogel Cancer Center; Center for RNA Biomedicine, University of Michigan, Ann Arbor, MI 48109,
Lipid nanoparticles (LNPs) have played an instrumental role in the delivery of RNA therapeutics and vaccines, including the emerging class of synthetic circular RNA (circRNA). Pulmonary vaccines hold the potential to prevent various respiratory infectious diseases, such as influenza caused by influenza infection. Here, we report the pulmonary delivery of LNPs loaded with highly stable small circRNA vaccine for influenza prevention.
View Article and Find Full Text PDFVaccine
September 2025
Institute of General Practice and Family Medicine, LMU University Hospital, LMU, Munich, Germany; German Center of Mental Health, Augsburg, Munich, Germany.
Background: Chronically ill are advised to receive annual vaccinations against Covid-19 and seasonal influenza. Furthermore, chronically ill show an increased prevalence of comorbid common mental disorders (CMDs), like depression, anxiety, and somatoform disorders. With vaccination rates remaining insufficient among these vulnerable patients, prior research assumes an association between CMDs and vaccination readiness.
View Article and Find Full Text PDF